← Back to Search

HyperSight Imaging arm for Head and Neck Cancers

N/A

Waitlist Available

Research Sponsored by Varian, a Siemens Healthineers Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patient has biopsy confirmed malignancy and recommendation for definitive or palliative radiation to the head and neck, breast, lungs, upper GI structures, or pelvis.

Patient has ECOG performance status 0-2.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial aims to test a new imaging technology called "HyperSight" that may improve the accuracy and quality of radiation therapy. Currently, there are limitations with the current imaging technology, including long acquisition

Who is the study for?

This trial is for individuals with various cancers (pelvic, head and neck, breast, lung, gastric, gastrointestinal tumors) who require precise radiation therapy. Participants should need image-guided radiation treatment but are not specified by other inclusion or exclusion criteria in the provided information.Check my eligibility

What is being tested?

The study is testing 'HyperSight Imaging,' a new type of imaging technology designed to improve the accuracy of radiation therapy. It aims to overcome limitations like long scan times and poor image quality seen with conventional cone beam computed tomography (CBCT).See study design

What are the potential side effects?

Since this trial focuses on an imaging technique rather than a drug or biological therapy, traditional side effects are not applicable. However, there may be risks associated with exposure to additional radiation from improved imaging if used frequently.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a confirmed cancer diagnosis and need radiation therapy in specific areas.

Select...

I am able to get out of my bed or chair and move around.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Fraction of patients whose HyperSight CBCT images meet the criteria for CBCT-based treatment planning.

Secondary outcome measures

Breath hold tolerance

Comparison of anatomical structure contours defined on HyperSight and conventional imaging.

Fraction of patients whose HyperSight CBCT images meet the criteria for CBCT-based treatment planning by anatomical site

+6 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: HyperSight Imaging armExperimental Treatment1 Intervention

Subjects are imaged with the new HyperSight CBCT imaging system.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Varian, a Siemens Healthineers CompanyLead Sponsor

30 Previous Clinical Trials

7,233 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new patients currently being actively recruited for this clinical trial?

"As per the information available on clinicaltrials.gov, this particular study is not currently seeking participants. It was initially posted on February 1st, 2024, and last edited on December 15th, 2023. However, it's worth noting that there are currently 2155 other trials actively enrolling participants at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluation of Improved Onboard Patient Imaging

2024. "Evaluation of Improved Onboard Patient Imaging". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06187103.

All > Gastric Cancer